MiNK Therapeutics
INKT
23 hedge funds and large institutions have $1.34M invested in MiNK Therapeutics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0.56% less ownership
Funds ownership: 3.26% → 2.7% (-0.56%)
8% less funds holding
Funds holding: 25 → 23 (-2)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
22% less capital invested
Capital invested by funds: $1.71M → $1.34M (-$373K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$63K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$34.5K |
| 3 |
SPIA
Steward Partners Investment Advisory
New York
|
+$22.3K |
| 4 |
AGWCA
Annis Gardner Whiting Capital Advisors
Tampa,
Florida
|
+$2.23K |
| 5 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$111 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$286K |
| 2 |
Renaissance Technologies
New York
|
-$116K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$6.33K |
| 4 |
Citigroup
New York
|
-$2.74K |
| 5 |
HFS
Horizon Financial Services
Winston Salem,
North Carolina
|
-$1.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Bank of America
Charlotte,
North Carolina
| – | -$6.33K | -568 | Closed |
|
|
HFS
27
Horizon Financial Services
Winston Salem,
North Carolina
| – | -$1.78K | -160 | Closed |
|
28
Wells Fargo
San Francisco,
California
| – | -$223 | -20 | Closed |
|
29
Barclays
London,
United Kingdom
| – | -$45 | -4 | Closed |
|
INKT Hedge Fund Activity: Q1 2026 in Review
23 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q1 2026, worth a combined $1.34M — down 22% from $1.71M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of INKT and 5 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $63K. The largest seller was DRW Securities, exiting entirely with an estimated $286K sold.
- 23 institutional investors held MiNK Therapeutics (INKT) as of Q1 2026, down from 25 in Q4 2025.
- Funds reported $1.34M of MiNK Therapeutics stock for Q1 2026, down 22% quarter-over-quarter.
- 5 funds opened new MiNK Therapeutics positions in Q1 2026 and 6 closed out, a net change of -1 holder.
- The largest MiNK Therapeutics buyer in Q1 2026 was UBS Group, an estimated $63K added.
- The largest MiNK Therapeutics seller in Q1 2026 was DRW Securities, an estimated $286K sold.
Based on aggregated 13F filings for Q1 2026.